VIRALGEN VECTOR CORE SL
VIRALGEN VECTOR CORE, S.L. is a Spanish private limited company (sociedad limitada) registered with the Registro Mercantil de Gipuzkoa under CIF B75181040. The company was incorporated on 27 June 2017 and its registered office is at Paseo Mikeletegi 83, 2º Planta, 20009 Donostia/San Sebastián, in the Basque Country. As of September 2026 its registry status is active, with registered share capital of €3,514.94 following a capital increase recorded on 6 February 2020.
The company’s filed corporate purpose covers the research, development, manufacture, use, promotion, marketing, sale and distribution of gene therapy products and related technologies, and it is classified under CNAE 7211 (research and experimental development in biotechnology). In practice, VIRALGEN VECTOR CORE, S.L. operates as a contract development and manufacturing organisation (CDMO) specialising in adeno-associated virus (AAV)-based gene therapy vectors, providing process development, analytical testing and clinical- to commercial-scale manufacturing services to gene-therapy developers.
VIRALGEN VECTOR CORE, S.L. manufactures from a campus in the Miramón technology park in San Sebastián comprising multiple European Medicines Agency (EMA) GMP-accredited facilities. According to public announcements from the company and its group, the site has received cGMP certification from the EMA for commercial-grade recombinant AAV (rAAV) production, and has been expanded in phases, with press reporting citing a multi-phase investment programme running into the tens of millions of euros. Deloitte Auditores, S.L. was appointed as the company’s statutory auditor, with the appointment recorded in commercial-registry filings dated 11 July 2025.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of VIRALGEN VECTOR CORE, S.L.
Spain does not require full public disclosure of a sociedad limitada’s complete shareholder register on free registry portals; fuller detail is filed with the Registro Mercantil and, above applicable thresholds, the Registro de Titularidades Reales. A commercial-registry data provider (northdata.com, compiling Registro Mercantil filings) records a single shareholder of record for VIRALGEN VECTOR CORE, S.L., consistent with the company operating as a wholly owned subsidiary, but the shareholder’s identity and holding percentage sit behind a paid subscription and were not independently confirmed from a freely accessible primary source for this profile (information as of 24 September 2026). Independent news reporting on completed corporate transactions (see the Group structure section) describes Bayer AG’s AskBio gene-therapy unit as having taken full ownership of the company in 2020, but this reporting does not itself constitute a share-register filing and is treated here as group-structure evidence rather than a confirmed shareholder listing.
Data availability
This information is classified as Restricted: a shareholder of record exists in the commercial-registry data reviewed, but the identity and ownership percentage are not accessible through the free public sources consulted for this profile.
Sources
- northdata.com – https://www.northdata.com/Viralgen+Vector+Core+SL,+Donostia/NIF+B75181040 – retrieved 2026-09-24
- infonif.economia3.com – https://infonif.economia3.com/ficha-empresa/viralgen-vector-core-sl – retrieved 2026-09-24
Officers
4
Directors and officers of VIRALGEN VECTOR CORE, S.L.
Commercial-registry aggregators report eleven administrators associated with VIRALGEN VECTOR CORE, S.L. as of mid-2026, though this profile was able to independently verify names and dates for only a subset via Boletín Oficial del Registro Mercantil (BORME)-sourced filings. Gustavo Jorge Pesquín was registered as Chair of the board on 18 September 2025. Holger Weintritt was registered as a board member on 9 April 2026. Iñaki Armendia Fernández de Viana was registered as company secretary (a non-board legal role under Spanish law) on 22 May 2026, together with María Eguren Aldazábal as vice-secretary, also a non-board role. Two individuals recorded in earlier registry data as active board members – Jozef Vanhove Jimmy and Javier García Cogorro – could not be independently reconfirmed as current for this review and are not presented as active here. The underlying filings reviewed are dated between September 2025 and May 2026.
Recent officer changes
- Gustavo Jorge Pesquín appointed Chair of the board – effective 18 September 2025 (BORME-sourced registry filing)
- Richard Jude Samulski, previously a board member, recorded as resigned – effective 25 February 2026 (BORME-sourced registry filing)
- Holger Weintritt appointed board member – effective 9 April 2026 (BORME-sourced registry filing)
Data availability
Spanish BORME filings do not disclose officer nationality; nationality is Not disclosed for all individuals named above. Aggregated registry counts report more administrators (eleven) than could be individually verified from the sources reviewed, so this information should be treated as Partial.
Sources
- infonif.economia3.com (BORME-sourced) – https://infonif.economia3.com/ficha-empresa/viralgen-vector-core-sl – retrieved 2026-09-24
- northdata.com – https://www.northdata.com/Viralgen+Vector+Core+SL,+Donostia/NIF+B75181040 – retrieved 2026-09-24
- Zavia internal registry data (Registro Mercantil-sourced), synced 2026-09-24
Group Structure
Group structure of VIRALGEN VECTOR CORE, S.L.
VIRALGEN VECTOR CORE, S.L. is not reported as an independent company. Official announcements from Bayer AG and multiple reputable news sources describe the company as part of the AskBio gene-therapy platform within the Bayer AG group, following Bayer’s 2020 acquisition of AskBio (Asklepios BioPharmaceutical, Inc., US) for approximately USD 4 billion and its related acquisition, within the same period, of the 50% stake in Viralgen previously held by the Spanish venture-capital fund Columbus Venture Partners. VIRALGEN VECTOR CORE, S.L. was originally founded in San Sebastián in 2017 as a joint venture equally owned by AskBio and Columbus Venture Partners. Bayer’s own media communications consistently refer to the company as “AskBio’s Viralgen,” identifying it with the AskBio platform. Bayer AG (Germany) is treated here as the verified ultimate parent on the strength of these official communications and corroborating news reporting of the completed transactions. The specific intermediate entity that directly holds VIRALGEN VECTOR CORE, S.L.’s shares, and the exact ownership percentage, were not confirmed from a primary ownership filing reviewed for this profile; a commercial-registry provider records a single shareholder of record for the company without disclosing its identity in the free content reviewed.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Bayer AG | DE | HRB 48248 (Amtsgericht Köln) | Ultimate parent (per official Bayer communications and reputable news reporting of completed transactions) | Not disclosed (news reporting describes full ownership following the 2020 transactions) | Active | 2026-09-24 |
| AskBio (Asklepios BioPharmaceutical, Inc.) | US | Not disclosed | Affiliate (Bayer AG’s gene-therapy platform; official communications describe it as encompassing Viralgen, not independently confirmed by a primary shareholding filing) | Not disclosed | Active | 2026-09-24 |
Recent structural changes
- Bayer AG announced the acquisition of AskBio – 2020 (reported transaction value approximately USD 4 billion)
- Bayer AG acquired the remaining 50% stake in Viralgen previously held by Columbus Venture Partners, consolidating full ownership within the Bayer AG group – 2020
Data availability
Corporate-linkage information for this company is classified as Partial: the ultimate parent (Bayer AG) is verified through official company announcements and reputable news reporting of completed transactions, but the immediate parent entity holding VIRALGEN VECTOR CORE, S.L.’s shares and the exact ownership percentage were not confirmed from a primary ownership filing reviewed for this profile.
Sources
- Bayer AG media release, “AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD” – https://www.bayer.com/media/en-us/askbios-viralgen-to-supply-commercial-scale-drug-product-for-regenerate-pd-investigational-gene-therapy-phase-ii-trial-for-parkinsons-disease/ – retrieved 2026-09-24
- Basque Health Cluster, “Bayer acquires BHC’s biotech affiliate, Viralgen” – https://www.basquehealthcluster.org/en/blog/news/bayer-acquires-bhcs-biotech-affiliate-viralgen/ – retrieved 2026-09-24
- Columbus Venture Partners, “Bayer boosts its gene therapy platform” – https://columbusvp.com/en/bayer-boosts-its-gene-therapy-platform/ – retrieved 2026-09-24
- northdata.com – https://www.northdata.com/Viralgen+Vector+Core+SL,+Donostia/NIF+B75181040 – retrieved 2026-09-24
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does VIRALGEN VECTOR CORE SL do?
Spanish CDMO (CIF B75181040, incorporated 27 June 2017, San Sebastian) specialising in adeno-associated virus (AAV)-based gene therapy vector manufacturing.
Who owns VIRALGEN VECTOR CORE SL?
A single shareholder of record is noted in commercial-registry data; the shareholder's identity is not disclosed in the free sources reviewed for this profile.
Who is VIRALGEN VECTOR CORE SL's UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) data is recorded for VIRALGEN VECTOR CORE SL; access to beneficial-ownership data in this jurisdiction is governed by its own register rules.
What is VIRALGEN VECTOR CORE SL's company registration number?
VIRALGEN VECTOR CORE SL's registration number is B75181040, filed with Colegio de Registradores / Registro Mercantil Central in Spain. Its current status on the register is active.
Is VIRALGEN VECTOR CORE SL still an active company?
VIRALGEN VECTOR CORE SL's status on Colegio de Registradores / Registro Mercantil Central is listed as active.
When was VIRALGEN VECTOR CORE SL incorporated?
VIRALGEN VECTOR CORE SL was incorporated on 1 January 2017, according to Colegio de Registradores / Registro Mercantil Central.
What is VIRALGEN VECTOR CORE SL's registered address?
The registered address on file for VIRALGEN VECTOR CORE SL is DONOSTIA/SAN SEBASTIÁN, Spain.
What legal structure is VIRALGEN VECTOR CORE SL registered as?
VIRALGEN VECTOR CORE SL is registered as a Private limited company (Ltd.) in Spain.
Who are the officers/directors of VIRALGEN VECTOR CORE SL?
Board chaired by Gustavo Jorge Pesquin (since 18 September 2025); commercial-registry aggregators report eleven administrators in total, of which only a subset could be independently verified.
Does VIRALGEN VECTOR CORE SL have a parent company or subsidiaries?
Described in Bayer AG's own communications as part of its AskBio gene-therapy platform, following Bayer's 2020 acquisition of AskBio and of Columbus Venture Partners' remaining stake in Viralgen.
Can Zavia monitor changes to VIRALGEN VECTOR CORE SL's ownership over time?
This profile reflects a point-in-time snapshot from Colegio de Registradores / Registro Mercantil Central. Zavia's monitoring API can track changes to VIRALGEN VECTOR CORE SL's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access VIRALGEN VECTOR CORE SL's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Spain, so records like VIRALGEN VECTOR CORE SL's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Colegio de Registradores / Registro Mercantil Central and was last synced on 24 September 2026.